{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T21:10:28Z","timestamp":1716325828355},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,6,26]],"date-time":"2017-06-26T00:00:00Z","timestamp":1498435200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s00108-017-0277-1","type":"journal-article","created":{"date-parts":[[2017,6,26]],"date-time":"2017-06-26T05:36:54Z","timestamp":1498455414000},"page":"990-999","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Neue medikament\u00f6se Therapieans\u00e4tze bei chronischer Herzinsuffizienz"],"prefix":"10.1007","volume":"58","author":[{"given":"T.","family":"Kempf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Bavendiek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bauersachs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,26]]},"reference":[{"key":"277_CR1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(15)00723-0","volume":"387","author":"WT Abraham","year":"2016","unstructured":"Abraham WT, Stevenson LW, Bourge RC et al (2016) Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet 387:453\u2013461","journal-title":"Lancet"},{"key":"277_CR2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/eurheartj\/ehi687","volume":"27","author":"A Ahmed","year":"2006","unstructured":"Ahmed A, Rich MW, Love TE et\u00a0al (2006) Digoxin and reduction in mortality and hospitalization in heart failure: a\u00a0comprehensive post hoc analysis of the DIG trial. Eur Heart\u00a0J 27:178\u2013186","journal-title":"Eur Heart J"},{"key":"277_CR3","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker SD, Comin Colet J, Filippatos G et\u00a0al (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N\u00a0Engl J Med 361:2436\u20132448","journal-title":"N Engl J Med"},{"key":"277_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.823","author":"SD Anker","year":"2017","unstructured":"Anker SD, Kirwan BA, van Veldhuisen DJ et al (2017) Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail. doi:\n                        10.1002\/ejhf.823","journal-title":"Eur J Heart Fail"},{"key":"277_CR5","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0140-6736(11)61229-4","volume":"378","author":"SD Anker","year":"2011","unstructured":"Anker SD, Koehler F, Abraham WT (2011) Telemedicine and remote management of patients with heart failure. Lancet 378:731\u2013739","journal-title":"Lancet"},{"key":"277_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw577","author":"U Bavendiek","year":"2017","unstructured":"Bavendiek U, Aguirre Davila L, Koch A et\u00a0al (2017) Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure. Eur Heart\u00a0J. doi:\n                        10.1093\/eurheartj\/ehw577","journal-title":"Eur Heart J"},{"key":"277_CR7","doi-asserted-by":"publisher","first-page":"e003529","DOI":"10.1161\/circheartfailure.116.003529","volume":"10","author":"H Burnett","year":"2017","unstructured":"Burnett H, Earley A, Voors AA et al (2017) Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis. Circ Heart Fail 10:e003529. doi:\n                        10.1161\/circheartfailure.116.003529","journal-title":"Circ Heart Fail"},{"key":"277_CR8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrcardio.2016.200","volume":"14","author":"DJ Campbell","year":"2017","unstructured":"Campbell DJ (2017) Long-term neprilysin inhibition \u2013 implications for ARNIs. Nat Rev Cardiol 14:171\u2013186","journal-title":"Nat Rev Cardiol"},{"key":"277_CR9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ejhf.687","volume":"19","author":"JA Cannon","year":"2017","unstructured":"Cannon JA, Shen L, Jhund PS et al (2017) Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Eur J Heart Fail 19:129\u2013137","journal-title":"Eur J Heart Fail"},{"key":"277_CR10","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/ejhf.567","volume":"18","author":"M Christ","year":"2016","unstructured":"Christ M, Stork S, Dorr M et\u00a0al (2016) Heart failure epidemiology 2000\u20132013: insights from the German Federal Health Monitoring System. Eur J Heart Fail 18:1009\u20131018","journal-title":"Eur J Heart Fail"},{"key":"277_CR11","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","volume":"357","author":"HJ Dargie","year":"2001","unstructured":"Dargie HJ (2001) Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357:1385\u20131390","journal-title":"Lancet"},{"key":"277_CR12","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","volume":"376","author":"S Denus de","year":"2017","unstructured":"de Denus S, O\u2019Meara E, Desai AS et\u00a0al (2017) Spironolactone metabolites in TOPCAT \u2013 new insights into regional variation. N\u00a0Engl J Med 376:1690\u20131692","journal-title":"N Engl J Med"},{"key":"277_CR13","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","volume":"36","author":"AS Desai","year":"2015","unstructured":"Desai AS, McMurray JJ, Packer M et al (2015) Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart\u00a0J 36:1990\u20131997","journal-title":"Eur Heart J"},{"key":"277_CR14","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","volume":"336","author":"G Digitalis Investigation","year":"1997","unstructured":"Digitalis Investigation G (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N\u00a0Engl J Med 336:525\u2013533","journal-title":"N Engl J Med"},{"key":"277_CR15","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-100900","author":"W Doehner","year":"2017","unstructured":"Doehner W, Blankenberg S, Erdmann E et al (2017) Iron deficiency in chronic heart failure: diagnostic algorithm and present-day therapeutic options. Dtsch Med Wochenschr. doi:\n                        10.1055\/s-0043-100900","journal-title":"Dtsch Med Wochenschr"},{"key":"277_CR16","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.jacc.2011.06.054","volume":"58","author":"F Edelmann","year":"2011","unstructured":"Edelmann F, Gelbrich G, Dungen HD et al (2011) Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J\u00a0Am Coll Cardiol 58:1780\u20131791","journal-title":"J Am Coll Cardiol"},{"key":"277_CR17","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","volume":"309","author":"F Edelmann","year":"2013","unstructured":"Edelmann F, Wachter R, Schmidt AG et al (2013) Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309:781\u2013791","journal-title":"JAMA"},{"key":"277_CR18","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","volume":"37","author":"D Fitchett","year":"2016","unstructured":"Fitchett D, Zinman B, Wanner C et al (2016) Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart\u00a0J 37:1526\u20131534","journal-title":"Eur Heart J"},{"key":"277_CR19","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr.","year":"2015","unstructured":"Group SR, Wright JT Jr., Williamson JD et al (2015) A randomized trial of intensive versus standard blood-pressure control. N\u00a0Engl J Med 373:2103\u20132116","journal-title":"N Engl J Med"},{"key":"277_CR20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0091270009343932","volume":"50","author":"J Gu","year":"2010","unstructured":"Gu J, Noe A, Chandra P et al (2010) Pharmacokinetics and pharmacodynamics of LCZ696, a\u00a0novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J\u00a0Clin Pharmacol 50:401\u2013414","journal-title":"J Clin Pharmacol"},{"key":"277_CR21","volume-title":"Deutscher Herzbericht","author":"Deutsche Herzstiftung","year":"2016","unstructured":"Deutsche Herzstiftung (2016) Deutscher Herzbericht"},{"key":"277_CR22","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/eurheartj\/ehv336","volume":"36","author":"ES Hoendermis","year":"2015","unstructured":"Hoendermis ES, Liu LC, Hummel YM et\u00a0al (2015) Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a\u00a0randomized controlled trial. Eur Heart\u00a0J 36:2565\u20132573","journal-title":"Eur Heart J"},{"key":"277_CR23","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","volume":"327","author":"S Investigators","year":"1992","unstructured":"Investigators S, Yusuf S, Pitt B et\u00a0al (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N\u00a0Engl J Med 327:685\u2013691","journal-title":"N Engl J Med"},{"key":"277_CR24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/jama.2015.17346","volume":"315","author":"DW Kitzman","year":"2016","unstructured":"Kitzman DW, Brubaker P, Morgan T et\u00a0al (2016) Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 315:36\u201346","journal-title":"JAMA"},{"key":"277_CR25","doi-asserted-by":"crossref","unstructured":"Laufs U, Anker SD, Falk V et al (2017) Kommentar zu den Leitlinien der Europ\u00e4ischen Gesellschaft f\u00fcr Kardiologie (ESC) zur Diagnostik und Behandlung der akuten und chronischen Herzinsuffizienz. Kardiologe 11:183\u2013192","DOI":"10.1007\/s12181-017-0143-3"},{"key":"277_CR26","doi-asserted-by":"crossref","unstructured":"Lewis GD, Malhotra R, Hernandez AF et al (2017) Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: The IRONOUT HF randomized clinical trial. JAMA 317:1958\u20131966","DOI":"10.1001\/jama.2017.5427"},{"key":"277_CR27","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N\u00a0Engl J Med 371:993\u20131004","journal-title":"N Engl J Med"},{"key":"277_CR28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","volume":"131","author":"M Packer","year":"2015","unstructured":"Packer M, McMurray JJ, Desai AS et\u00a0al (2015) Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131:54\u201361","journal-title":"Circulation"},{"key":"277_CR29","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","volume":"372","author":"DK Packham","year":"2015","unstructured":"Packham DK, Rasmussen HS, Lavin PT et\u00a0al (2015) Sodium zirconium cyclosilicate in hyperkalemia. N\u00a0Engl J Med 372:222\u2013231","journal-title":"N Engl J Med"},{"key":"277_CR30","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1161\/CIRCULATIONAHA.115.015853","volume":"132","author":"A Pandey","year":"2015","unstructured":"Pandey A, Garg S, Khunger M et al (2015) Dose-response relationship between physical activity and risk of heart failure: a meta-analysis. Circulation 132:1786\u20131794","journal-title":"Circulation"},{"key":"277_CR31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","volume":"62","author":"WJ Paulus","year":"2013","unstructured":"Paulus WJ, Tschope C (2013) A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J\u00a0Am Coll Cardiol 62:263\u2013271","journal-title":"J Am Coll Cardiol"},{"key":"277_CR32","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","volume":"131","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Assmann SF et\u00a0al (2015) Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation 131:34\u201342","journal-title":"Circulation"},{"key":"277_CR33","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF et\u00a0al (2014) Spironolactone for heart failure with preserved ejection fraction. N\u00a0Engl J Med 370:1383\u20131392","journal-title":"N Engl J Med"},{"key":"277_CR34","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","volume":"36","author":"P Ponikowski","year":"2015","unstructured":"Ponikowski P, van Veldhuisen DJ, Comin-Colet J et al (2015) Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger. Eur Heart\u00a0J 36:657\u2013668","journal-title":"Eur Heart J"},{"key":"277_CR35","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD et\u00a0al (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart\u00a0J 37:2129\u20132200","journal-title":"Eur Heart J"},{"key":"277_CR36","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/jama.289.7.871","volume":"289","author":"SS Rathore","year":"2003","unstructured":"Rathore SS, Curtis JP, Wang Y et\u00a0al (2003) Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289:871\u2013878","journal-title":"JAMA"},{"key":"277_CR37","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","volume":"309","author":"MM Redfield","year":"2013","unstructured":"Redfield MM, Chen HH, Borlaug BA et al (2013) Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a\u00a0randomized clinical trial. JAMA 309:1268\u20131277","journal-title":"JAMA"},{"key":"277_CR38","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","volume":"37","author":"SD Solomon","year":"2016","unstructured":"Solomon SD, Claggett B, Lewis EF et\u00a0al (2016) Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart\u00a0J 37:455\u2013462","journal-title":"Eur Heart J"},{"key":"277_CR39","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","volume":"380","author":"SD Solomon","year":"2012","unstructured":"Solomon SD, Zile M, Pieske B et al (2012) The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a\u00a0phase 2 double-blind randomised controlled trial. Lancet 380:1387\u20131395","journal-title":"Lancet"},{"key":"277_CR40","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.jacc.2012.01.020","volume":"59","author":"K Swedberg","year":"2012","unstructured":"Swedberg K, Komajda M, Bohm M et al (2012) Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: Is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J\u00a0Am Coll Cardiol 59:1938\u20131945","journal-title":"J Am Coll Cardiol"},{"key":"277_CR41","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, Bohm M et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a\u00a0randomised placebo-controlled study. Lancet 376:875\u2013885","journal-title":"Lancet"},{"key":"277_CR42","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nrcardio.2015.109","volume":"12","author":"S Haehling von","year":"2015","unstructured":"von Haehling S, Jankowska EA, van Veldhuisen DJ et\u00a0al (2015) Iron deficiency and cardiovascular disease. Nat Rev Cardiol 12:659\u2013669","journal-title":"Nat Rev Cardiol"},{"key":"277_CR43","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","volume":"372","author":"MR Weir","year":"2015","unstructured":"Weir MR, Bakris GL, Bushinsky DA et\u00a0al (2015) Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N\u00a0Engl J Med 372:211\u2013221","journal-title":"N Engl J Med"},{"key":"277_CR44","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000000509","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B et\u00a0al (2017) 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. Circulation. doi:\n                        10.1161\/cir.0000000000000509","journal-title":"Circulation"},{"key":"277_CR45","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et\u00a0al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N\u00a0Engl J Med 373:2117\u20132128","journal-title":"N Engl J Med"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-017-0277-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-017-0277-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-017-0277-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,30]],"date-time":"2017-08-30T04:26:10Z","timestamp":1504067170000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-017-0277-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,26]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["277"],"URL":"https:\/\/doi.org\/10.1007\/s00108-017-0277-1","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,26]]}}}